Skip to main content
DYAI
NASDAQ Life Sciences

Dyadic Regains Nasdaq Compliance, Resolving Delisting Threat

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.23
Mkt Cap
$44.091M
52W Low
$0.655
52W High
$1.6
52W Position info
88% above low
Off High info
23% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

DYAI sits 88% above its 52-week low of $0.655.

Summary

Dyadic International announced that Nasdaq has confirmed the company regained compliance with listing rules, resolving the delisting threat that began in June 2026. The stock will continue trading on the Nasdaq Capital Market.


Key Events · Legal and Risk Events · DYAI

  • Nasdaq Compliance Regained

    Nasdaq confirmed Dyadic has regained compliance with Listing Rules 5550(a)(2) (minimum bid price) and 5550(b) (minimum equity), ending the delisting process initiated on June 18, 2026.

  • Delisting Threat Resolved

    The company's common stock will continue to be listed and traded on the Nasdaq Capital Market, removing a critical risk that had pressured the stock.

  • Reverse Split Enabled Compliance

    Shareholder approval of a reverse stock split on June 22, 2026, was the key mechanism that allowed Dyadic to meet the minimum bid price requirement.

  • Business Focus Restored

    CEO Mark Emalfarb stated the company can now focus on executing its business strategy, developing products, and expanding commercial adoption of its C1 and Dapibus platforms.


Analysis · DYAI · Life Sciences

A critical existential risk has been lifted for Dyadic International, as Nasdaq confirmed the company has regained compliance with its minimum bid price and equity rules. The delisting threat, which had been hanging over the stock since June 18, 2026, is now resolved, allowing shares to continue trading on the Nasdaq Capital Market. This outcome follows shareholder approval of a reverse stock split on June 22—the key mechanism that enabled the company to meet the requirements. With the listing secure, management can now turn its full attention to executing the business strategy without the overhang of a potential delisting.

At the time of this filing, DYAI was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.1M. The 52-week trading range was $0.65 to $1.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYAI - Latest Insights

DYAI
Jul 07, 2026, 7:25 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.965
Real-time Price: $1.21 info
Change: +$0.2463 (+26%) info
Market Cap: $44.091M info
DYAI
Jun 22, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7976
Real-time Price: $1.21 info
Change: +$0.4137 (+52%) info
Market Cap: $44.091M info
DYAI
Jun 18, 2026, 10:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.865
Real-time Price: $1.21 info
Change: +$0.3463 (+40%) info
Market Cap: $44.091M info
DYAI
Jun 18, 2026, 9:56 AM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $0.8485
Real-time Price: $1.21 info
Change: +$0.3628 (+43%) info
Market Cap: $44.091M info
DYAI
Jun 18, 2026, 9:55 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8485
Real-time Price: $1.21 info
Change: +$0.3628 (+43%) info
Market Cap: $44.091M info